Retatrutide Research

Retatrutide (research designation LY3437943) is a synthetic peptide agonist at three separate receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. That combination is why it is usually described in the literature as a triple agonist or tri-agonist, and why it is studied alongside rather than instead of dual-agonist peptides.

This hub organises the Biovanta Research library for retatrutide: what the molecule is, how its receptor activity is characterised, what the published research programme has reported so far, how the peptide behaves as laboratory material, and how it compares with the other incretin peptides in our catalogue.

Research categories

Start here

Foundational resources covering the molecule and its receptor pharmacology.

• What is Retatrutide? — Definition, research designation, peptide class and receptor targets of retatrutide as a laboratory research compound.
• Mechanism of Action — How retatrutide engages the GIP, GLP-1 and glucagon receptors, and what that combined signalling is understood to do.
• Molecular Structure — Sequence features, lipidation and structural modifications that define the retatrutide molecule.
• What Does Retatrutide Do? — What retatrutide does at each of its three receptors, and what the published research reports about the combined signal.
• How Does Retatrutide Work? — Step-by-step account of receptor binding, cAMP signalling, albumin binding and clearance for retatrutide.
• Retatrutide Peptide Profile — Reference profile for retatrutide as a peptide: designation, class, receptor targets, format and batch testing.

Research & studies

What the published and registered research record currently reports.

• Published Research — An overview of the peer-reviewed retatrutide research record, from receptor pharmacology to phase 2 trials.

Development & regulatory status

Who develops retatrutide, where the research programme currently stands, and what its regulatory status actually is.

• Who Makes Retatrutide? — Who develops retatrutide as an investigational compound, and who manufactures the peptide sold as research material.
• Eli Lilly and Retatrutide (LY3437943) — The Eli Lilly retatrutide programme: the LY3437943 designation, published characterisation and registered studies.
• Is Retatrutide Approved? — Current regulatory status of retatrutide: investigational, not approved as a medicine in the UK, US or EU.
• Retatrutide FDA Approval Status — Why retatrutide does not appear in Drugs@FDA, and how FDA approval status for an investigational peptide is verified.
• When Will Retatrutide Be Available? — What public trial and regulatory records do and do not say about a future retatrutide availability date.

Receptor research

Each receptor target examined separately, then in combination.

• Retatrutide Receptors — The three receptors retatrutide is designed to activate, what each one does, and why the balance between them defines the molecule.
• GLP-1 Receptor — The GLP-1 receptor: expression, signalling and its role in incretin peptide research.
• GIP Receptor — GIP receptor biology and why GIP activity is included in dual and triple agonist design.
• Glucagon Receptor — Hepatic glucagon receptor signalling and its role in the retatrutide profile.
• Triple Receptor Agonism — What triple receptor agonism means in peptide design, and how balance between receptors is characterised.
• Is Retatrutide a GLP-1? — Why retatrutide is more accurately described as a triple receptor agonist than as a GLP-1 agonist, and what the distinction changes.
• "GLP-3" Explained — Why retatrutide is informally nicknamed "GLP-3", why no GLP-3 hormone or receptor exists, and what the correct terminology is.

Comparative research

Controlled cross-silo resources. Each comparison exists once, in the silo of the compound it leads with.

• Retatrutide vs Tirzepatide — Triple versus dual receptor agonism: how retatrutide and tirzepatide differ in receptor targets and study design.
• Retatrutide vs GLP-1 Agonists — How a triple receptor agonist differs pharmacologically from the single-receptor GLP-1 agonist class, and what that changes in study design.

Peptide chemistry & pharmacology

Structural and pharmacological reference data for laboratories characterising or handling retatrutide research material.

• Molecular Weight — Reported molecular weight of retatrutide, how it is confirmed analytically, and how to use it in reconstitution calculations.
• Amino Acid Sequence — What is publicly documented about retatrutide’s 39-residue sequence, its GIP-derived backbone and its lipidation site.
• Pharmacology — Receptor pharmacology, reported potency framework and pharmacokinetic design features of retatrutide as an investigational peptide.

Laboratory research

Handling characteristics that determine whether a result is reproducible.

• Storage — Storage conditions for lyophilised and reconstituted retatrutide in a laboratory setting.

UK research information

Regulatory and supply context for laboratories working in the United Kingdom.

• Retatrutide in the UK — Supply, testing and dispatch context for retatrutide research material in the United Kingdom.
• Regulatory Status (UK) — The regulatory position of retatrutide as an unlicensed investigational compound supplied for research use only.

Retatrutide research material · Certificates of analysis · All research hubs

Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.